QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor

Abstract

We read with interest Monzani et al's report1 on QT pro-longation in COVID-19 patients on treatment with chloro-quine/hydroxychloroquine (CQ/HCQ). Her report highlights the therapeutic morbidities that have unfortunately evolved as part of the measures to control COVID-19 pandemic. Cardiac toxicity including QTc prolongation has been well established as part of the syndrome of adverse events associated with CQ/HCQ administration.2 Since the advent of the COVID-19 pandemic, there has been increasing reports of various phe-notypes of QTc prolongation and its sequelae in COVID-19 patients on treatment with CQ/HCQ.